Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of Emflaza in Young Boys with DMD
NCT03642145Phase 3Withdrawn
- Sponsor
- PTC Therapeutics, Inc.
- Start
- Oct 2018
- Primary completion
- Jul 2021
- Modality
- Orthosteric Ligands
01
Overview
A Phase 3 trial of deflazacort in Duchenne muscular dystrophy (DMD), sponsored by PTC Therapeutics, Inc.. Planned start Oct 2018; status: withdrawn.
02
Drugs
deflazacort
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT03642145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03642145.